Edwards Lifesciences (NYSE:EW) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Edwards Lifesciences (NYSE:EW) from a buy rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other equities research analysts have also weighed in on the company. UBS Group assumed coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. BTIG Research reiterated a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences in a report on Friday, September 11th. Finally, Citigroup boosted their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $86.39 on Friday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $88.43 and a 200-day moving average price of $85.99. The company has a market cap of $49.75 billion, a price-to-earnings ratio of 49.65, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. Edwards Lifesciences has a 12 month low of $72.30 and a 12 month high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 5,664 shares of company stock valued at $511,918. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pin Oak Investment Advisors Inc. bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $26,000. TrinityBridge Ltd bought a new stake in Edwards Lifesciences during the second quarter worth about $27,000. MV Capital Management Inc. bought a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the first quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.